comparemela.com

Latest Breaking News On - Assessment of spondyloarthritis international society - Page 8 : comparemela.com

U S FDA Approves Pfizer s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis

Peripheral Manifestations Influence Spondyloarthritis Trajectory

MRI sacroiliitis, HLA-B27 predict long-term response to certolizumab pegol in axial SpA

In patients with non-radiographic axial spondyloarthritis, MRI sacroiliitis and HLA-B27 positivity, but not elevated C-reactive protein or responses at week 12, predict long-term certolizumab pegol response, according to data. “Non-radiographic axial spondyloarthritis can be a challenging diagnosis in the absence of radiographic sacroiliitis and selecting patients for treatment with

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.